Liquidia Corporation (LQDA) - Stock Analysis
Last updated: Jun 28, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin expansion ⢠Cash generation ⢠Leverage risk LQDA delivered a sharp turnaround in profitability and cash flow with improved liquidity, but its high leverage and demanding valuation still make the stock risky.
Price Behavior
Key Price Behavior Insights: ⢠Bullish breakout ⢠Higher lows ⢠Stretched rally Support Level: $74-$75 Resistance Level: $78.17 Over the last month, LQDA broke above prior resistance, formed higher lows, and surged to $78.17, signaling strong bullish momentum but short-term overbought risk.
Sentiment & News
Key News Insights: ⢠Index Inclusion ⢠Momentum Interest ⢠Pipeline Visibility Liquidia Corp's June headlines point to improving market recognition, boosted by S&P SmallCap 600 inclusion, modest stock strength, and continued biotech/conference visibility.
AI Summary
LQDA has shifted from a speculative biotech into a real commercial execution story with strong profitability and free cash flow, but at >200x earnings the stock now depends on YUTREPIA sustaining rapid growth with little room for any operational miss or slower uptake.
Description
Liquidia Corporation is a U.S.-based biopharmaceutical company that develops, manufactures and commercializes therapies to address unmet clinical needs. Its portfolio includes an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension and it also markets generic treprostinil injection domestically. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 23 | Jun 30 | LQDA | Liquidia Corporation | Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion. | Active | +5.6% |
| Jun 16 | Jun 23 | LQDA | Liquidia Corporation | Constructive biotech momentum with a near-term index catalyst: Q1 2026 net product sales were about $130M, the company posted a third consecutive profitable quarter, and S&P SmallCap 600 inclusion is effective 2026-06-22. Shares are up about 20% over 21 trading days and remain above short-term trend. | Closed | +8.9% |
| Jun 8 | Jun 15 | LQDA | Liquidia Corporation | Commercial biotech momentum supported by strong YUTREPIA execution: latest quarter showed about $130M in net product sales, EPS beat consensus ($0.52 vs. $0.34), profitability improved for a third straight profitable quarter, and the stock is up about 50% over 21 trading days. | Closed | +12.4% |
| Jun 1 | Jun 8 | LQDA | Liquidia Corporation | Biotech/commercial momentum name with strong recent execution: YUTREPIA sales were about $130M-$133M, prescriptions exceeded 4,500, profitability reached a third straight quarter, adjusted EBITDA was positive, and free cash flow was strong. Stock is up about 56% over 21 trading days. | Closed | +8.8% |
| May 22 | May 29 | LQDA | Liquidia Corporation | Strong biotech execution and momentum: Q1 2026 showed about $130M of YUTREPIA net sales, more than 4,500 unique prescriptions, a third straight profitable quarter, and improved cash; stock is up about 66% over 21 trading days. | Closed | +1.4% |
| May 13 | May 20 | LQDA | Liquidia Corporation | Strong operating inflection and price momentum: Q1 2026 YUTREPIA net product sales were about $130M, with more than 4,500 unique prescriptions, a third straight profitable quarter, net income around $53M, adjusted EBITDA of $71M, and free cash flow near $50M. Shares are up about 41% over 21 trading days. | Closed | +7.3% |